HK1211035A1 - ANTIBODIES TO INTEGRIN V6 AND USE OF SAME TO TREAT CANCER v6 - Google Patents
ANTIBODIES TO INTEGRIN V6 AND USE OF SAME TO TREAT CANCER v6Info
- Publication number
- HK1211035A1 HK1211035A1 HK15111593.1A HK15111593A HK1211035A1 HK 1211035 A1 HK1211035 A1 HK 1211035A1 HK 15111593 A HK15111593 A HK 15111593A HK 1211035 A1 HK1211035 A1 HK 1211035A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- integrin
- antibodies
- same
- treat cancer
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600499P | 2012-02-17 | 2012-02-17 | |
| US201261602511P | 2012-02-23 | 2012-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1211035A1 true HK1211035A1 (en) | 2016-05-13 |
Family
ID=48984888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15111593.1A HK1211035A1 (en) | 2012-02-17 | 2015-11-25 | ANTIBODIES TO INTEGRIN V6 AND USE OF SAME TO TREAT CANCER v6 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9493566B2 (xx) |
| EP (1) | EP2814509B1 (xx) |
| JP (1) | JP6273214B2 (xx) |
| KR (1) | KR102084806B1 (xx) |
| CN (2) | CN105017420B (xx) |
| AU (1) | AU2013221585B2 (xx) |
| BR (1) | BR112014019861A2 (xx) |
| CA (1) | CA2862319C (xx) |
| EA (1) | EA031069B1 (xx) |
| HK (1) | HK1211035A1 (xx) |
| IL (1) | IL233742B (xx) |
| MX (1) | MX360141B (xx) |
| SG (1) | SG11201404354UA (xx) |
| WO (1) | WO2013123152A2 (xx) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2294178B1 (en) | 2008-05-23 | 2014-07-16 | Siwa Corporation | Methods for facilitating regeneration |
| EP3052523B1 (en) * | 2013-10-01 | 2021-03-10 | Medimmune Limited | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
| CA2921707C (en) | 2013-10-15 | 2023-03-28 | Seattle Genetics, Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| KR20240036143A (ko) | 2014-02-17 | 2024-03-19 | 씨젠 인크. | 친수성 항체-약물 컨쥬게이트 |
| US20170233452A1 (en) * | 2014-04-23 | 2017-08-17 | Immusoft Corporation | Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| MX2018006218A (es) | 2015-12-04 | 2018-09-05 | Seattle Genetics Inc | Conjugados de compuestos de tubulisina cuaternizada. |
| WO2017143073A1 (en) | 2016-02-19 | 2017-08-24 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
| UA125510C2 (uk) | 2016-03-25 | 2022-04-13 | Сіджен Інк. | Спосіб отримання пегильованої сполуки лікарський препарат-лінкер, де лікарським препаратом є ауристатин, та її проміжних сполук |
| KR20180133452A (ko) | 2016-04-15 | 2018-12-14 | 시와 코퍼레이션 | 신경퇴행성 질환을 치료하기 위한 항-노화 항체 |
| EA201990470A1 (ru) | 2016-08-09 | 2019-09-30 | Сиэтл Дженетикс, Инк. | Конъюгаты лекарственного средства с самостабилизирующимися линкерами, имеющие улучшенные физико-химические свойства |
| US11638762B2 (en) | 2016-10-18 | 2023-05-02 | Seagen Inc. | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
| ES2906109T3 (es) * | 2016-11-01 | 2022-04-13 | Arrowhead Pharmaceuticals Inc | Ligandos de la integrina alfa- v beta-6 y usos de los mismos |
| WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
| US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| EP3609923A1 (en) * | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| WO2018201087A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| EP3703700A4 (en) * | 2017-11-01 | 2021-08-04 | Arrowhead Pharmaceuticals, Inc. | INTEGRIN LIGANDS AND USES THEREOF |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| EP3755707A1 (en) | 2018-02-20 | 2020-12-30 | Seagen Inc. | Hydrophobic auristatin f compounds and conjugates thereof |
| BR112022009570A2 (pt) * | 2019-12-05 | 2022-08-02 | Seagen Inc | Anticorpo anti-¿v¿6 isolado ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-¿v¿6 ou fragmento de ligação ao antígeno, para produção de um conjugado anticorpo anti-¿v¿6-fármaco e para tratamento de câncer em um indivíduo, e, composição farmacêutica |
| EP4087657A1 (en) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| IL297167A (en) | 2020-04-10 | 2022-12-01 | Seagen Inc | Charging variant connectors |
| WO2022226100A1 (en) | 2021-04-20 | 2022-10-27 | Seagen Inc. | Modulation of antibody-dependent cellular cytotoxicity |
| AU2022283467A1 (en) | 2021-05-28 | 2023-12-07 | Seagen Inc. | Anthracycline antibody conjugates |
| US20230381321A1 (en) | 2022-03-17 | 2023-11-30 | Seagan Inc., | Camptothecin conjugates |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| WO2024137442A1 (en) | 2022-12-21 | 2024-06-27 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
| ATE511850T1 (de) | 1997-08-08 | 2011-06-15 | Univ California | Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin |
| ES2318006T3 (es) * | 2001-04-30 | 2009-05-01 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el peptido beta-amiloide. |
| CA2478833C (en) * | 2002-03-13 | 2015-11-10 | Biogen, Inc. | Anti-.alpha.v.beta.6 antibodies |
| CN100509851C (zh) * | 2002-03-13 | 2009-07-08 | 拜奥根Idec马萨诸塞公司 | 抗αvβ6抗体 |
| AU2003230929A1 (en) | 2002-04-12 | 2003-10-27 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| US7241598B2 (en) * | 2004-06-29 | 2007-07-10 | The Chinese University Of Hong Kong | Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering |
| ZA200703561B (en) * | 2004-10-05 | 2009-09-30 | Wyeth Corp | Methods and compositions for improving recombinant protein production |
| NZ555601A (en) * | 2004-12-09 | 2009-07-31 | Centocor Inc | Anti-integrin immunoconjugates, methods and uses |
| EP2322560B1 (en) * | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| AU2006286498A1 (en) | 2005-08-31 | 2007-03-08 | Novo Nordisk Health Care Ag | Human FVII monoclonal antibodies binding the GLA domain and use thereof |
| ES2746925T3 (es) | 2006-08-03 | 2020-03-09 | Medimmune Ltd | Anticuerpos dirigidos hacia alfaVbeta6 y uso de los mismos |
| CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| AU2007354317A1 (en) | 2006-10-19 | 2008-12-04 | Biogen Idec Ma Inc. | Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6 |
| EP2241578B1 (en) * | 2008-01-11 | 2016-04-20 | The University of Tokyo | Anti-cldn6 antibody |
| BRPI0906498A2 (pt) * | 2008-01-22 | 2015-07-14 | Biogen Idec Inc | Anticorpo ron e seus usos |
| WO2009119258A1 (ja) | 2008-03-27 | 2009-10-01 | テルモ株式会社 | 生体吸収性材料およびそれを用いた生体内留置物 |
| CA2723842A1 (en) | 2008-05-09 | 2009-11-12 | Peter Vanlandschoot | Amino acid sequences directed against integrins and uses thereof |
| JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| KR101138460B1 (ko) | 2009-10-12 | 2012-04-26 | 한국생명공학연구원 | 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 |
| WO2011046309A2 (en) * | 2009-10-12 | 2011-04-21 | Korea Research Institute Of Bioscience And Biotechnology | A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof |
| SG10201509499RA (en) | 2010-11-19 | 2015-12-30 | Eisai R&D Man Co Ltd | Neutralizing anti-ccl20 antibodies |
| WO2013148316A1 (en) | 2012-03-29 | 2013-10-03 | Biogen Idec Ma Inc. | Biomarkers for use in integrin therapy applications |
-
2013
- 2013-02-14 CN CN201510418545.9A patent/CN105017420B/zh active Active
- 2013-02-14 EA EA201491541A patent/EA031069B1/ru unknown
- 2013-02-14 AU AU2013221585A patent/AU2013221585B2/en active Active
- 2013-02-14 MX MX2014009751A patent/MX360141B/es active IP Right Grant
- 2013-02-14 KR KR1020147025536A patent/KR102084806B1/ko active IP Right Grant
- 2013-02-14 SG SG11201404354UA patent/SG11201404354UA/en unknown
- 2013-02-14 EP EP13749647.7A patent/EP2814509B1/en active Active
- 2013-02-14 WO PCT/US2013/026087 patent/WO2013123152A2/en active Application Filing
- 2013-02-14 BR BR112014019861A patent/BR112014019861A2/pt not_active IP Right Cessation
- 2013-02-14 CN CN201380009160.6A patent/CN104220094A/zh active Pending
- 2013-02-14 CA CA2862319A patent/CA2862319C/en active Active
- 2013-02-14 US US14/378,746 patent/US9493566B2/en active Active
- 2013-02-14 JP JP2014557760A patent/JP6273214B2/ja active Active
-
2014
- 2014-07-22 IL IL233742A patent/IL233742B/en active IP Right Grant
-
2015
- 2015-11-25 HK HK15111593.1A patent/HK1211035A1/xx unknown
-
2016
- 2016-09-07 US US15/258,699 patent/US20160376368A1/en not_active Abandoned
-
2019
- 2019-09-30 US US16/588,331 patent/US20200031938A1/en not_active Abandoned
-
2021
- 2021-01-08 US US17/144,869 patent/US20210340260A1/en not_active Abandoned
-
2023
- 2023-02-17 US US18/170,742 patent/US20230242648A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105017420B (zh) | 2019-05-28 |
| CA2862319A1 (en) | 2013-08-22 |
| MX2014009751A (es) | 2015-02-24 |
| EA031069B1 (ru) | 2018-11-30 |
| US20160009806A1 (en) | 2016-01-14 |
| AU2013221585A1 (en) | 2014-08-14 |
| US20230242648A1 (en) | 2023-08-03 |
| CN104220094A (zh) | 2014-12-17 |
| US20160376368A1 (en) | 2016-12-29 |
| BR112014019861A2 (pt) | 2017-07-04 |
| IL233742B (en) | 2019-08-29 |
| SG11201404354UA (en) | 2014-10-30 |
| WO2013123152A3 (en) | 2014-11-13 |
| EP2814509A4 (en) | 2015-12-09 |
| EA201491541A1 (ru) | 2016-05-31 |
| EP2814509B1 (en) | 2018-05-16 |
| US20200031938A1 (en) | 2020-01-30 |
| IL233742A0 (en) | 2014-09-30 |
| CN105017420A (zh) | 2015-11-04 |
| US20210340260A1 (en) | 2021-11-04 |
| JP6273214B2 (ja) | 2018-01-31 |
| KR102084806B1 (ko) | 2020-03-04 |
| CA2862319C (en) | 2021-11-30 |
| EP2814509A2 (en) | 2014-12-24 |
| JP2015509938A (ja) | 2015-04-02 |
| US9493566B2 (en) | 2016-11-15 |
| AU2013221585B2 (en) | 2017-03-30 |
| MX360141B (es) | 2018-10-24 |
| KR20140127875A (ko) | 2014-11-04 |
| WO2013123152A2 (en) | 2013-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1211035A1 (en) | ANTIBODIES TO INTEGRIN V6 AND USE OF SAME TO TREAT CANCER v6 | |
| HK1206750A1 (en) | Cd33 antibodies and use of same to treat cancer cd33 | |
| IL237960B (en) | Combination of anti-kir antibodies and anti-pd-1 antibodies for cancer treatment | |
| ZA201501858B (en) | Anti-mcam antibodies and associated methods of use | |
| ZA201408236B (en) | Anti-ly6e antibodies and immunoconjugates and methods of use | |
| HK1215856A1 (zh) | 抗血凝素抗體和使用方法 | |
| IL238227A0 (en) | Antibodies against c16orf54 and uses thereof | |
| PT2806892T (pt) | Uso terapêutico combinado de anticorpos e endoglicosidases | |
| HK1211989A1 (en) | Antibodies to aripiprazole and use thereof | |
| ZA201404675B (en) | Anti-lrp5 antibodies and methods of use | |
| EP2874650A4 (en) | FOR CD22 SPECIFIC ANTIBODIES AND METHOD FOR USE THEREOF | |
| EP2938632A4 (en) | ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE | |
| HK1209432A1 (en) | Anti-jagged antibodies and methods of use | |
| HK1213584A1 (zh) | 用於治療癌症的 抗體及方法 |